Artificial Intelligence and Antibiotic Discovery

Area of Science:

• Microbiology
• Pharmacology
• Computer Science

Background:

• The global antibiotic crisis is driven by decreased research, low investment returns, and inappropriate antibiotic use, leading to widespread antimicrobial resistance.
• Antimicrobial resistance poses severe public health threats, increasing healthcare costs and risking a return to the pre-antibiotic era.
• Traditional antibiotic discovery is lengthy, costly, and has a low success rate for new drug candidates.

Purpose of the Study:

• To provide a comprehensive overview of current artificial intelligence (AI)-based technologies in antibiotic discovery.
• To analyze the technological and economic impact of AI on the pharmaceutical industry in the context of antibiotic development.
• To highlight AI's potential to accelerate the discovery of novel antibiotics and address the growing crisis.

Main Methods:

• Review of existing literature on AI applications in drug discovery, specifically for antibiotics.
• Analysis of AI algorithms used for identifying hit compounds and predicting antimicrobial activity.
• Examination of case studies demonstrating the integration of AI in pharmaceutical research and development.

Main Results:

• AI technologies can significantly reduce the time and cost associated with antibiotic research and development.
• AI algorithms demonstrate efficacy in identifying novel hit compounds and optimizing drug candidates.
• The integration of AI is transforming the industrial sector, offering new economic models for antibiotic development.

Conclusions:

• AI presents a promising avenue to overcome the challenges of the antibiotic crisis by accelerating the discovery of new antibiotics.
• The adoption of AI technologies is crucial for enhancing research efficiency and economic viability in antibiotic development.
• Continued collaboration between academic and health institutions, leveraging AI, is essential to avert a post-antibiotic era.